360° Coverage : Glaxo Effort To Verify Gene Data Represents Step For Open Science

2 Updates

Glaxo Effort To Verify Gene Data Represents Step For Open Science

Mar 27 2014, 6:11am CDT | by

GlaxoSmithKline’s efforts to fund a 50-person effort with two top universities to verify that the proteins it is picking as targets for drugs are actually involved in the diseases the company hopes...

Filed under: news

 
 
 

29 weeks ago

Glaxo Effort To Verify Gene Data Represents Step For Open Science

Mar 27 2014, 6:11am CDT | by

GlaxoSmithKline’s efforts to fund a 50-person effort with two top universities to verify that the proteins it is picking as targets for drugs are actually involved in the diseases the company hopes to treat are a big example of the Big Pharma dropping its veil of research secrecy.

The new Centre for Therapeutic Target Validation is a collaboration between the London-based drug giant, the Wellcome Trust Sanger Institute, which is one of the top genetics research hotspots in the world, and the European Bioinformatics Institute. The effort will take a “Big Data” approach to pooling genetic data and other information to pick drug targets.

“[Glaxo are] providing people and expertise based analysts with this incredible wealth of expertise,” says Ewan Birney, who will be the interim head of the center. “They’ve been doing this for a long time and the’ve had successes and they’ve had failures and, in some sense, they’ll be bringing those into the public domain. I’ve been surprised at how engaged GSK has been scientifically and how interesting this problem is to handle.”

Almost all medicines work by blocking or otherwise affecting specific proteins. For instance, statin drugs like Lipitor block an enzyme in the liver that helps the body create cholesterol; aspirin blocks enzymes involved in causing inflammation and clotting blood.

But one big problem for drug researchers is that they often aren’t sure they understand what the proteins they are targeting with experimental medicines do. Problems in the quality of public research, which can be wrong, can make this worse. This project hopes that big data — looking at information and especially human genetics — can make the odds of success for new medicines better.

Patrick Vallance, who heads basic research at GSK, says that in the past ten years genetics has gone from being “quite misleading” to “high throughput” and “reliable.”

“Every week there are something like three new rare genetic mutations causing a very rare disease are being identified,” says Vallance. “Every week there is new data coming up on common disease genetic variations. What that does is it creates massive information that is truly about human biology. All of a sudden you get a window into things that are genuinely causal across a range of diseases.”

Of course, fifteen years ago drug company research executives, including those at Glaxo, made similar claims about the sequencing of the human genome and the data produced by a slew of hot gene data companies. That led to a great many failures, some of which took years to read out. For Glaxo, the reminders of its deals with Human Genome Sciences are recent: the lupus drug Benlysta, which worked but has not generated much in the way of sales, and darapladib, a much hyped heart drug that recently failed in a big trial and that also, it turned out, had the unfortunate side effect of making patients smell bad.

But Vallance provides a strong argument that things are different this time. Creating drugs has always been about finding the right proteins to target, he says. Now genetics has become the best way to do that.

Birney insists that genetics provides something that other methods of biology don’t. When you look at a person’s genes, they’ll be for the most part the same throughout life. So when a gene is linked to a disease, it gives a real clue as to how the biology of a disease works. That’s how rare mutations that cause super-high cholesterol led to the cholesterol-lowering statins, and that’s how Birney and Vallance hope that this effort will lead to new drugs.

It used to be that drug companies tried to keep much of their biology research in-house and secret, so that they would start synthesizing promising new compounds before competitors. But this effort puts a lot more of Glaxo’s research out in the open. The bet is that the advantages of having lots of minds working on the problems of drug discovery will outweigh any advantages that secrecy would have provided.

Source: Forbes Business

 
Update
2

7 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashing the workforce of 20,000 by 3 ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 
Update
1

7 weeks ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of th ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Spanish nurse cured of Ebola
Madrid, Oct 21 (Xinhua) Spanish nursing auxiliary Teresa Romero was pronounced cured of the Ebola virus disease according to World Health Organisation (WHO) guidelines after the results of a second test confirmed Tuesday that she no longer had the virus in her blood.
 
 
Clinical trials of Ebola vaccine start Nov 1 in Switzerland
Geneva, Oct 21 (IANS/EFE) The World Health Organisation (WHO) announced Tuesday that it will begin clinical trials Nov 1 in Switzerland of one of the two anti-Ebola vaccines currently under development.
 
 
Colombia to launch world's first floating gas liquefaction plant
Bogota, Oct 21 (IANS/EFE) The world's first floating gas liquefaction plant is due to begin operating next year off the coast of northern Colombia under a pact between Canada-based Pacific Rubiales Energy and Belgian shipbuilder Exmar.
 
 
Paralysed man walks again after pioneering cell therapy
London, Oct 21 (IANS/EFE) A paralysed man has been able to walk again after therapy that involved transplanting cells from his nasal cavity into his spinal cord, the BBC reported Tuesday.
 
 
 

Latest from the Network

Keira Knightley was 'a goody two-shoes'
Keira Knightley was ''a goody two-shoes'' when she was younger. The 29-year-old actress claims she was a ''boring'' well-behaved child and never skipped school because she didn't want to upset her parents or teachers....
Read more on Celebrity Balla
 
Kat Dennings is in love with Kim Kardashian
Kat Dennings thinks Kim Kardashian's butt is ''amazing.'' The '2 Broke Girls' actress was ''very nervous'' when the 'Keeping Up with the Kardashians' star filmed a cameo for the show's 80th episode and was too shy to...
Read more on Celebrity Balla
 
Taylor Swift doesn't 'need some guy' for inspiration
Taylor Swift is ''figuring out how to cope'' with life on her own. The 'Shake It Off' hitmaker hopes her upcoming album, '1989,' will prove she doesn't ''need some guy'' to help her ''make a great record'' or to feel...
Read more on Celebrity Balla
 
Sarah Hyland is 'great'
Sarah Hyland says she is ''great'' after obtaining a restraining order against her ex-boyfriend. The 'Modern Family' star is happy to be focusing on her career again after a judge recently granted her a three-year...
Read more on Celebrity Balla
 
India re-elected to UNHRC for two years
United Nations, Oct 21 (IANS) India was Tuesday re-elected to the United Nations Human Rights Council (UNHRC) for the term 2015-2017 in a keenly contested election in the UN General Assembly in New York. Other...
Read more on Politics Balla
 
Spanish nurse cured of Ebola
Madrid, Oct 21 (Xinhua) Spanish nursing auxiliary Teresa Romero was pronounced cured of the Ebola virus disease according to World Health Organisation (WHO) guidelines after the results of a second test confirmed...
Read more on Business Balla
 
Gurdwara closed in Belgium
Brussels, Oct 21 (IANS) The mayor of the town of Vilvoorde in Belgium, Hans Bonte, has ordered the closure of the local gurdwara, Guru Nanak Sahib, for one month. Belgian media Tuesday charged that the Sikh temple "...
Read more on Politics Balla
 
Air strikes kill 28 militants in Pakistan
Islamabad, Oct 21 (IANS) At least 28 militants were killed when the Pakistani army launched an air strike in the country's northwest tribal town of Datta Khel Tuesday, military said. In a statement, Inter Services...
Read more on Politics Balla
 
Report reveals large-scale torture in China's 'Black Jails'
Beijing, Oct 21 (IANS/EFE) The use of hotels and factories as clandestine prisons where thousands of people -- mostly women -- are tortured to prevent their complaints against the government from coming to light has...
Read more on Politics Balla
 
Clinical trials of Ebola vaccine start Nov 1 in Switzerland
Geneva, Oct 21 (IANS/EFE) The World Health Organisation (WHO) announced Tuesday that it will begin clinical trials Nov 1 in Switzerland of one of the two anti-Ebola vaccines currently under development. WHO Assistant...
Read more on Business Balla